Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19772869 | 0.74 | AR (0.35) | — | |
| SCHEMBL2633081 | 0.70 | MAPK1 (0.38) | — | |
| SCHEMBL762009 | 0.69 | MAPT (0.42) | — | |
| SCHEMBL13672554 | 0.69 | CHEK1 (0.41) | CACNA1HCACNA1CCACNA1GPDE10A | |
| SCHEMBL22292145 | 0.68 | MAPT (0.36) | — | |
| SCHEMBL21497446 | 0.68 | QPCT (0.36) | — | |
| SCHEMBL762334 | 0.67 | PARP1 (0.46) | — | |
| SCHEMBL25702614 | 0.66 | L3MBTL1 (0.35) | — | |
| SCHEMBL6750187 | 0.64 | MAPT (0.40) | — | |
| SCHEMBL19262922 | 0.63 | SCN10A (0.38) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | CACNA1H 4748/4885CACNA1C 4682/4885CACNA1G 4740/4885 |
| US-10208011-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | CACNA1H 1110/4885CACNA1C 1815/4885CACNA1G 1235/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | CACNA1H 3563/4885CACNA1C 3971/4885CACNA1G 3522/4885 |
| US-10633362-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | CACNA1H 1110/4885CACNA1C 1815/4885CACNA1G 1235/4885 |
| US-20190119243-A1 | BENZOTHIOPHENE ESTROGEN RECEPTOR MODULATORS | ESR1, GPER1, ESR2 | CACNA1H 1110/4885CACNA1C 1815/4885CACNA1G 1235/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | CACNA1H 4854/4885CACNA1C 4862/4885CACNA1G 4845/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | CACNA1H 4878/4885CACNA1C 4885/4885CACNA1G 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.